Gene editing just took a step out of rare disease — and into everyday medicine.
On November 9, 2026, CRISPR Therapeutics presented Phase 1b data for CTX310 in a late-breaking oral presentation at the American Heart Association Scientific Sessions in Chicago. CTX310 is an investigational in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3 (angiopoietin-like protein 3), delivered as a single intravenous infusion. In ten participants with severe hypertriglyceridemia — fasting triglycerides above 500 mg/dL at entry, median baseline above 1,000 mg/dL, all with diabetes — a single course produced mean reductions from baseline at Day 30 of 65% in circulating ANGPTL3 and 63% in triglycerides. Non-HDL cholesterol fell about 51%, apolipoprotein B about 23%, LDL cholesterol about 16%. The reductions were maintained in the seven participants followed for at least 90 days. The treatment was well tolerated, with no treatment-related serious adverse events and no clinically relevant elevations in liver enzymes.
I want to be plain about what this is not. It is not a treatment you can get — CTX310 is investigational and available only through clinical trials. It is not proof of lasting benefit: ten people, open-label, no comparison group, thirty days of follow-up for everyone and ninety days for seven, reported by the company at a conference and not yet peer-reviewed. The honest read is that this is a strong early signal in a very small, very sick group of people.
And yet the signal matters, because of where it points. CASGEVY, the world's first approved CRISPR therapy, treats sickle cell disease and beta thalassemia. It did $99 million in revenue in the third quarter of 2026, up 30% quarter-over-quarter. CTX310 is the move from that world into this one: lipids and cholesterol affect millions, not thousands. Phase 1a one-year durability data were presented at the ESC Congress 2026 and published in the New England Journal of Medicine. The FDA recently granted CTX310 Regenerative Medicine Advanced Therapy designations for severe hypertriglyceridemia and for elevated LDL cholesterol. The science is not inching forward. It is crossing a line — from rare disease, where gene editing began, into common disease, where most patients live.
A one-time edit asks different questions than a daily pill, and as a Health Informaticist those are the questions I keep coming back to. A pill you stop taking stops working. An edit to a liver gene does not stop. That permanence is the promise: no daily dose, no lifetime of refills, no adherence gap. It is also the responsibility. Who follows a patient edited once, for life? Where does that follow-up live — in the trial sponsor's database, in the health system's record, in a registry nobody funds after year five? Who holds the consent when the consequence lasts decades? And who pays for a treatment given once, at a price that will almost certainly be set like other one-time therapies — high, upfront, and out of reach for most?
In my years of direct patient care, I watched good treatments reach the wrong patients first. Not because anyone intended it, but because access follows infrastructure, and infrastructure follows money. The centers that run the trials are the centers that learn the therapy first, hire for it first, and build the referral pathways first. By the time a treatment like this reaches ten thousand people, the pattern of who got it is usually already set — and it is very hard to un-set.
That is why the access conversation cannot wait for the Phase 3 readout. The economics change when the patient population goes from thousands to millions: the price negotiation changes, the payer conversation changes, the question of who is left out changes. A therapy that works once and lasts a lifetime will be the most valuable kind of medicine there is. The organizations and systems that ask now — while the trial has ten people in it — who gets it first, who pays, and who tracks the patient for life, will be the ones that do not have to retrofit fairness onto a finished rollout.
The standards exist for the science. The FDA designations are in hand, the durability data are accumulating, and the trial continues in the United States and abroad. What does not exist yet, in most health systems, is an owner for the questions that follow the science: the lifetime follow-up, the data stewardship, the equity plan. Gene editing is leaving rare disease behind. The conversation about who benefits cannot afford to arrive after it does.
Want to explore what readiness looks like for your organization? Book a free Discovery Call — no pressure, just an honest conversation about where you are and what comes next.
Valencia Annik Payne, MS Health Informatics/Healthcare Administration, BSN, RN
Certified AI Consultant™ | Healthcare AI Strategist | U.S. Navy Nurse Veteran
Learn more at https://www.rn4studentsnanosolutions.com/

